Skip to main content
. 2021 Mar 22;10:100128. doi: 10.1016/j.lanwpc.2021.100128

Fig. 2.

Fig. 2

Efficacy of IGU at week 12 and week 24. (A) ACR20/50/70 response rate of all patients at week 12 and week 24; (B) DAS28 disease activity of patients at baseline, week 12, and week 24(Remission, DAS28≤2•6; Low disease activity 2•6<DAS28≤3•2; Moderate disease activity, 3•2<DAS28≤5•1; and High disease activity, DAS28>5•1);(C) ACR/EULAR remission rate of patients at baseline, week 4, week 8, week 12, week 16 and week 24. * P<0•05 compared with week 12. ACR=American College of Rheumatology; DAS28=Disease Activity Score 28 joints; DR=disease duration; EULAR=European League Against Rheumatism; IGU=Iguratimod.